563 related articles for article (PubMed ID: 27057683)
1. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
2. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
[TBL] [Abstract][Full Text] [Related]
3. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
5. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
6. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
[TBL] [Abstract][Full Text] [Related]
7. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Hofmekler T; Bertha M; McCracken C; Martineau B; McKinnon E; Schoen BT; McElhanon BO; Tenjarla G; Kugathasan S; Sauer CG
J Pediatr Gastroenterol Nutr; 2017 Apr; 64(4):580-585. PubMed ID: 28079601
[TBL] [Abstract][Full Text] [Related]
8. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
Gomes LEM; da Silva FAR; Pascoal LB; Ricci RL; Nogueira G; Camargo MG; Lourdes Setsuko Ayrizono M; Fagundes JJ; Leal RF
Clinics (Sao Paulo); 2019 Apr; 74():e824. PubMed ID: 30994711
[TBL] [Abstract][Full Text] [Related]
9. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
[TBL] [Abstract][Full Text] [Related]
10. Serum infliximab concentrations in pediatric inflammatory bowel disease.
Hämäläinen A; Sipponen T; Kolho KL
Scand J Gastroenterol; 2013 Jan; 48(1):35-41. PubMed ID: 23148710
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
12. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
13. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
[TBL] [Abstract][Full Text] [Related]
14. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
Merras-Salmio L; Kolho KL
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
[TBL] [Abstract][Full Text] [Related]
15. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
Teixeira FV; Sassaki LY; Saad-Hossne R; Baima JP; Magro DO; Coy CSR; Kotze PG
Arq Gastroenterol; 2018; 55(2):192-197. PubMed ID: 30043873
[TBL] [Abstract][Full Text] [Related]
16. Infliximab levels and antibodies in IBD-related peripheral arthralgia.
Levartovsky A; Ungar B; Yavzori M; Picard O; Fudim E; Eliakim R; Paul S; Roblin X; Ben-Horin S; Kopylov U
Int J Colorectal Dis; 2020 Jun; 35(6):1141-1148. PubMed ID: 32296932
[TBL] [Abstract][Full Text] [Related]
17. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
Vahabnezhad E; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Apr; 20(4):606-13. PubMed ID: 24552827
[TBL] [Abstract][Full Text] [Related]
18. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
[TBL] [Abstract][Full Text] [Related]
19. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
20. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
